KITLG and neuroblastoma: Inhibition of KIT activity by different agents, such as specific RTK inhibitors [9,10,11,12,17], targeted antibodies [18], SCF-conjugated bacterial toxins [19], and interfering RNAs [6], leads to decrease in NB cells proliferation rate and tumor growth in vivo [6,9,10,19].